WuXi Biologics (Cayman) Inc. provided unaudited consolidated earnings guidance for the six months ended June 30, 2021. For the six months, it is expected that the profit attributable to equity shareholders of the Company for the six months ended June 30, 2021 will increase more than 135% compared with the profit attributable to equity shareholders of the Company for the corresponding period of last year.